Agilent Technologies Secures Patent for CGH Assays
21-08-2012: Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research.
The U.S. patent (No. 8,232,055) has claims for measuring copy number changes in genomic DNA, covering both one-color and two-color assays using oligonucleotide probes and samples with high-sequence complexity, such as human genomic DNA samples.
Agilent’s copy number method, commercially introduced in 2005, uses long oligonucleotide probes, enabling high specificity and sensitivity. For example, samples containing as low as 8 percent abnormal cells may be confidently analyzed with Agilent’s copy number method.
The method was originally developed to improve upon older copy number assays that use long genomic fragments such as bacterial artificial chromosomes. (BACs often contain repetitive regions.) The method also improves upon other oligonucleotide array assays, which depend on sample preparation methods that remove significant portions of the genomic DNA content. Agilent’s higher-resolution platform allows users to detect much smaller genomic aberrations throughout complex genomes.
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2Thermo Fisher Scientific and Samsung Electronics to Collaborate on Point-of-Care Diagnostic Solutions
- 3QIAGEN makes proposal to fully acquire Ipsogen
- 4LGC rebrands reference standards
- 5Towards future lab-on-chip applications
- 6Failed Alzheimer’s test shows in which direction the research should continue
- 7Renishaw receives Queen's Award for spectroscopy developments
- 8The shadow of a disease
- 9Expansion of the WALDNER Group
- 10LIMS/LIS Market and POCT Supplement
- SP Industries Appoints New Chief Operating Officer
- JPK announces the opening of US offices in Southern California
- IDT and Ubiquitome Partner to Develop Mobile Ebola Test
- Thermo Fisher Scientific and Samsung Electronics to Collaborate on Point-of-Care Diagnostic Solutions
- Major class of fracking chemicals no more toxic than common household substances